**Introduction and Highlights**

- Felezonexor (SL-801) is a novel XPO1 inhibitor that offers the potential for an improved safety profile compared to XPO1 inhibitors currently in development.
- Felezonexor has demonstrated activity in multiple solid tumor indications.
- Dose escalation and regimen optimization continues with Schedule B, now expanded, with 75 mg/day cohort currently enrolled.
- Manageable safety and tolerability profile demonstrated thus far.
- Phase 1 trial of felezonexor is ongoing in heavily pretreated patients with solid tumors.

**Background**

Felezonexor (SL-801) is a selective and reversible XPO1 inhibitor with potential for activity across multiple solid tumor indications. The drug is designed to inhibit the nuclear export of tumor suppressor proteins, including p53, APC, Rb, BRCA1, and FOXO family proteins, and is cytotoxic against solid and hematologic malignancies. Felezonexor is being evaluated in a phase 1 trial for patients with advanced solid tumors who have failed prior systemic therapy and are considered poor candidates for traditional treatments.

**Mechanism of Action and Rational**

- XPO1 is a clinically validated target in multiple cancer types.
- Felezonexor has demonstrated clinical activity in hematologic malignancies and solid tumors.
- Felezonexor offers a potentially improved safety and tolerability profile compared to existing XPO1 inhibitors.

**Dosing, Safety, and Tolerability**

- Felezonexor is being administered in a once-daily oral dose regimen.
- Dose escalation continues using Schedule B, now expanded, with 75 mg/day cohort currently enrolled.
- Manageable safety and tolerability profile demonstrated thus far.

**Safety and Tolerability**

- Treatment-related adverse events (TRAEs) have been reported.
- Most common treatment-related adverse events (TRAEs) include:
  - Gastrointestinal: nausea, vomiting, fatigue, dehydration, and anorexia.
  - Hematologic: lymphopenia, neutropenia, and anemia.

**Overview of Disease Control**

- Dose and tumor histology:
  - N = 39
  - BRCA = 11
  - MSS = 6
  - KRAS = 6
  - Wild-type = 10
  - Other = 6

**Pharmacokinetics**

- Felezonexor is a novel XPO1 inhibitor that offers the potential for an improved safety profile compared to XPO1 inhibitors currently in development.
- Felezonexor has demonstrated activity in multiple solid tumor indications.
- Dose escalation and regimen optimization continues with Schedule B, now expanded, with 75 mg/day cohort currently enrolled.
- Manageable safety and tolerability profile demonstrated thus far.

**Conclusion**

Felezonexor (SL-801) is a novel XPO1 inhibitor that offers the potential for an improved safety profile compared to XPO1 inhibitors currently in development. The drug is designed to inhibit the nuclear export of tumor suppressor proteins, including p53, APC, Rb, BRCA1, and FOXO family proteins, and is cytotoxic against solid and hematologic malignancies. Felezonexor is being evaluated in a phase 1 trial for patients with advanced solid tumors who have failed prior systemic therapy and are considered poor candidates for traditional treatments.